HRP20140589T1 - Derivati pirazinooksazepina - Google Patents
Derivati pirazinooksazepina Download PDFInfo
- Publication number
- HRP20140589T1 HRP20140589T1 HRP20140589AT HRP20140589T HRP20140589T1 HR P20140589 T1 HRP20140589 T1 HR P20140589T1 HR P20140589A T HRP20140589A T HR P20140589AT HR P20140589 T HRP20140589 T HR P20140589T HR P20140589 T1 HRP20140589 T1 HR P20140589T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- optionally substituted
- compound
- salt
- salt according
- Prior art date
Links
- SCHSCDGSDQJULH-UHFFFAOYSA-N pyrazino[2,3-f]oxazepine Chemical class O1N=CC=CC2=NC=CN=C12 SCHSCDGSDQJULH-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 25
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 7
- -1 (3) pyrrolidinyl group Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 230000006866 deterioration Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000005936 piperidyl group Chemical group 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 210000001635 urinary tract Anatomy 0.000 claims 2
- NOEUVPQJHSVLGU-UHFFFAOYSA-N 3-(2-methylpiperidin-1-yl)-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine Chemical group CC1CCCCN1C1=CN=C(CNCCO2)C2=N1 NOEUVPQJHSVLGU-UHFFFAOYSA-N 0.000 claims 1
- VGFIKRZKRMJZHU-UHFFFAOYSA-N 3-(2-methylpyrrolidin-1-yl)-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine Chemical group CC1CCCN1C1=CN=C(CNCCO2)C2=N1 VGFIKRZKRMJZHU-UHFFFAOYSA-N 0.000 claims 1
- QVNQPALRUZXHNM-UHFFFAOYSA-N 3-(3-ethylmorpholin-4-yl)-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine Chemical group CCC1COCCN1C1=CN=C(CNCCO2)C2=N1 QVNQPALRUZXHNM-UHFFFAOYSA-N 0.000 claims 1
- KIBUUUXWUBWXAD-UHFFFAOYSA-N 3-(3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine Chemical group CC1COCCN1C1=CN=C(CNCCO2)C2=N1 KIBUUUXWUBWXAD-UHFFFAOYSA-N 0.000 claims 1
- ABLHVWPHYYAENK-UHFFFAOYSA-N 3-cyclopropyl-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine Chemical group C1CC1C1=CN=C(CNCCO2)C2=N1 ABLHVWPHYYAENK-UHFFFAOYSA-N 0.000 claims 1
- OGHVGSWIIZAUTG-UHFFFAOYSA-N 3-propan-2-yloxy-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine Chemical group C1NCCOC2=NC(OC(C)C)=CN=C21 OGHVGSWIIZAUTG-UHFFFAOYSA-N 0.000 claims 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 claims 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 claims 1
- BCUDVZFYCXXVFO-UHFFFAOYSA-N 6-methyl-3-(3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine Chemical group CC1COCCN1C1=CN=C(CNCC(C)O2)C2=N1 BCUDVZFYCXXVFO-UHFFFAOYSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- IONFSPILJMPKCA-UHFFFAOYSA-N n-methyl-n-propan-2-yl-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepin-3-amine Chemical group C1NCCOC2=NC(N(C)C(C)C)=CN=C21 IONFSPILJMPKCA-UHFFFAOYSA-N 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (18)
1. Spoj, naznačen time, da je predstavljen formulom (I0):
[image]
gdje
R1 je sljedeće:
(1) morfolinil-skupina opcijski supstituirana s jednom ili više C1-6 alkil-skupina,
(2) piperidil-skupina opcijski supstituirana s jednom ili više C1-6 alkil-skupina,
(3) pirolidinil-skupina opcijski supstituirana s jednom ili više C1-6 alkil-skupina koje su opcijski supstituirane s jednom ili više C1-6 alkoksi-skupina,
(4) pirolil-skupina opcijski supstituirana s jednom ili više C1-6 alkil-skupina,
(5) imidazolil-skupina opcijski supstituirana s jednom ili više C1-6 alkil-skupina,
(6) amino-skupina opcijski supstituirana s 1 ili 2 supstituenta odabrana od sljedećih:
(a) C1-6 alkil-skupina opcijski supstituirana s jednim ili više supstituenata odabranima od C3-6 cikloalkil-skupine i fenilne skupine, i
(b) C3-6 cikloalkil-skupina,
(7) C1-6 alkilsulfanil-skupina,
(8) C1-6 alkoksi-skupina opcijski supstituirana s jednom ili više C3-6 cikloalkil-skupina,
(9) C3-6 cikloalkil-skupina, ili
(10) C3-6 cikloalkenil-skupina;
R2' je atom vodika ili C1-6 alkil-skupina opcijski supstituirana s jednom ili više C1-6 alkoksi-skupina, i
R3' je atom vodika, atom halogena ili C1-6 alkil-skupina, ili njegova sol.
2. Spoj ili sol prema zahtjevu 1, naznačen time, da R1 je sljedeće:
(1) morfolinil-skupina opcijski supstituirana s jednom ili više C1-6 alkil-skupina,
(2) piperidil-skupina supstituirana s jednom ili više C1-6 alkil-skupina,
(3) pirolidinil-skupina supstituirana s jednom ili više C1-6 alkil-skupina koje su opcijski supstituirane s jednom ili više C1-6 alkoksi-skupina,
(4) pirolil-skupina supstituirana s jednom ili više C1-6 alkil-skupina,
(5) imidazolil-skupina supstituirana s jednom ili više C1-6 alkil-skupina,
(6) amino-skupina opcijski supstituirana s 1 ili 2 supstituenta odabrana od sljedećih:
(a) C1-6 alkil-skupina opcijski supstituirana s jednim ili više supstituenata odabranima od C3-6 cikloalkil-skupine i fenilne skupine, i
(b) C3-6 cikloalkil-skupina,
(7) C1-6 alkilsulfanil-skupina,
(8) C1-6 alkoksi-skupina opcijski supstituirana s jednom ili više C3-6 cikloalkil-skupina,
(9) C3-6 cikloalkil-skupina, ili
(10) C3-6 cikloalkenil-skupina.
3. Spoj ili sol prema zahtjevu 1, naznačen time, da je spoj predstavljen formulom (I)
[image]
gdje
R1 je morfolino-skupina opcijski supstituirana s jednom ili više C1-6 alkil-skupina, di(C1-6 alkil)amino-skupina, C1-6 alkoksi-skupina opcijski supstituirana s jednom ili više C3-6 cikloalkil-skupina, C3-6 cikloalkil-skupina ili C3-6 cikloalkenil-skupina; i R2 je atom vodika ili C1-6 alkil-skupina.
4. Spoj ili sol prema zahtjevu 3, naznačen time, da R1 je morfolino-skupina opcijski supstituirana s jednom ili više C1-6 alkil-skupina, di(C1-6 alkil)amino-skupina, C1-6 alkoksi-skupina ili C3-6 cikloalkil-skupina.
5. Spoj ili sol prema zahtjevu 3, naznačen time, da R1 je morfolino-skupina opcijski supstituirana s jednim ili više supstituenata odabranima između metilne skupine i etilne skupine, N-metil-N-(1-metiletil)amino-skupina, izopropoksi- skupina ili ciklopropil-skupina; i R2 je atom vodika ili metilna skupina.
6. Spoj ili sol prema zahtjevu 1, naznačen time, da je to 3-(1-metiletoksi)-6,7,8,9-tetrahidropirazino[2,3-f][1,4]oksazepin ili njegova sol.
7. Spoj ili sol prema zahtjevu 1, naznačen time, da je to 3-(3-metilmorfolin-4-il)-6,7,8,9-tetrahidropirazino[2,3-f][1,4]oksazepin ili njegova sol.
8. Spoj ili sol prema zahtjevu 1, naznačen time, da je to 6-metil-3-(morfolin-4-il)-6,7,8,9-tetrahidropirazino[2,3-f][1,4] oksazepin ili njegova sol.
9. Spoj ili sol prema zahtjevu 1, naznačen time, da je to 6-metil-3-(3-metilmorfolin-4-il)-6,7,8,9-tetrahidropirazino[2,3-f][1,4]oksazepin ili njegova sol.
10. Spoj ili sol prema zahtjevu 1, naznačen time, da je to N-metil-N-(1-metiletil)-6,7,8,9-tetrahidropirazino[2,3-f][1,4]oksazepin-3-amin ili njegova sol.
11. Spoj ili sol prema zahtjevu 1, naznačen time, da je to 3-(3-etilmorfolin-4-il)-6,7,8,9-tetrahidropirazino[2,3-f][1,4]oksazepin ili njegova sol.
12. Spoj ili sol prema zahtjevu 1, naznačen time, da je to 3-ciklopropil-6,7,8,9- tetrahidropirazino[2,3-f][1,4]oksazepin ili njegova sol.
13. Spoj ili sol prema zahtjevu 1, naznačen time, da je to 3-(2-metilpiperidin-1-il)-6,7,8,9-tetrahidropirazino[2,3-f][1,4]oksazepin ili njegova sol.
14. Spoj ili sol prema zahtjevu 1, naznačen time, da je to 3-(2-metilpirolidin-1-il)-6,7,8,9-tetrahidropirazino[2,3-f][1,4]oksazepin ili njegova sol.
15. Lijek, naznačen time, da obuhvaća spoj ili sol prema jednom od zahtjeva 1 do 14.
16. Lijek prema zahtjevu 15, naznačen time, da je to aktivator receptora serotonina 5-HT2C.
17. Lijek prema zahtjevu 15, naznačen time, da se upotrebljava za profilaksu ili liječenje simptoma spuštenog urinarnog trakta, pretilosti i/ili propadanja organa.
18. Spoj ili sol prema bilo kojem od zahtjeva 1 do 14, naznačen time, da se upotrebljava za profilaksu ili liječenje simptoma spuštenog urinarnog trakta, pretilosti i/ili propadanja organa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009142673 | 2009-06-15 | ||
| PCT/JP2010/060408 WO2010147226A1 (en) | 2009-06-15 | 2010-06-14 | Pyrazinooxazepine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140589T1 true HRP20140589T1 (hr) | 2014-08-01 |
Family
ID=42561089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140589AT HRP20140589T1 (hr) | 2009-06-15 | 2014-06-23 | Derivati pirazinooksazepina |
Country Status (41)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2018863B9 (en) * | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
| NZ597507A (en) * | 2009-06-15 | 2013-09-27 | Takeda Pharmaceutical | Pyrazinooxazepine derivatives |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| JP2014201578A (ja) * | 2013-04-09 | 2014-10-27 | 武田薬品工業株式会社 | 線維筋痛症治療剤 |
| JP2014214132A (ja) * | 2013-04-26 | 2014-11-17 | 武田薬品工業株式会社 | ニコチン依存症の予防・治療剤 |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| WO2017026538A1 (en) | 2015-08-07 | 2017-02-16 | Takeda Pharmaceutical Company Limited | Production method of pyrazine |
| WO2017111178A1 (en) | 2015-12-24 | 2017-06-29 | Takeda Pharmaceutical Company Limited | Solid preparation |
| US9985579B2 (en) | 2016-04-12 | 2018-05-29 | Preformed Line Products Co. | Mounting assembly for mounting a solar panel |
| EP3733204A4 (en) * | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2992677B2 (ja) | 1995-06-05 | 1999-12-20 | 武田薬品工業株式会社 | 骨形成促進医薬組成物 |
| SE0002754D0 (sv) | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
| KR100831909B1 (ko) | 2000-11-20 | 2008-05-26 | 바이오비트럼 에이비(피유비엘) | 세로토닌 5-ｈｔ2 수용체의 안타고니스트로서의피페라지닐피라진 화합물 |
| AU2002314744A1 (en) | 2001-04-17 | 2002-10-28 | Sepracor, Inc. | Thiazole and other heterocyclic ligands and use thereof |
| SE0201544D0 (sv) | 2002-05-17 | 2002-05-17 | Biovitrum Ab | Novel compounds and thier use |
| IL165220A0 (en) | 2002-06-19 | 2005-12-18 | Biovitrum Ab | Novel compounds, their use and preparation |
| WO2004000829A1 (en) | 2002-06-19 | 2003-12-31 | Biovitrum Ab | Novel process |
| WO2004067008A1 (ja) | 2003-01-28 | 2004-08-12 | Takeda Pharmaceutical Company Limited | 受容体作動薬 |
| CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
| EA016558B1 (ru) * | 2003-06-17 | 2012-05-30 | Арена Фармасьютикалз, Инк. | Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором |
| AU2004267016B2 (en) * | 2003-06-17 | 2011-11-24 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases |
| JP2006056881A (ja) | 2004-07-21 | 2006-03-02 | Takeda Chem Ind Ltd | 縮合環化合物 |
| SI1926712T1 (sl) * | 2005-09-01 | 2010-01-29 | Lilly Co Eli | 6-substituirani 2,3.4,5-tetrahidro-1h-benzo(d)azepini kot agonisti 5-ht2c receptorja |
| FR2895259B1 (fr) | 2005-12-22 | 2008-02-22 | Urosphere Sas | Methodes de traitement des incontinences urinaires |
| EP2018863B9 (en) * | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
| US8247403B2 (en) | 2007-03-07 | 2012-08-21 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
| US20090062253A1 (en) | 2007-08-31 | 2009-03-05 | Kalypsys, Inc. | Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease |
| US20100266504A1 (en) | 2007-11-15 | 2010-10-21 | Takahiro Matsumoto | Condensed pyridine derivative and use thereof |
| WO2009063993A1 (ja) | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | 縮合ピリジン誘導体およびその用途 |
| US8329687B2 (en) * | 2007-11-15 | 2012-12-11 | Takeda Pharmaceutical Company Limited | Pyridooxazepine derivative and use thereof |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| NZ597507A (en) * | 2009-06-15 | 2013-09-27 | Takeda Pharmaceutical | Pyrazinooxazepine derivatives |
-
2010
- 2010-06-14 NZ NZ597507A patent/NZ597507A/xx not_active IP Right Cessation
- 2010-06-14 PT PT107271546T patent/PT2442870E/pt unknown
- 2010-06-14 BR BRPI1011502A patent/BRPI1011502A2/pt not_active Application Discontinuation
- 2010-06-14 JP JP2012514674A patent/JP5579262B2/ja not_active Expired - Fee Related
- 2010-06-14 SG SG2011090149A patent/SG176696A1/en unknown
- 2010-06-14 TW TW099119242A patent/TWI542592B/zh not_active IP Right Cessation
- 2010-06-14 JO JOP/2010/0194A patent/JO3087B1/ar active
- 2010-06-14 EA EA201270017A patent/EA021079B1/ru not_active IP Right Cessation
- 2010-06-14 MA MA34535A patent/MA33430B1/fr unknown
- 2010-06-14 US US13/377,918 patent/US9115139B2/en not_active Expired - Fee Related
- 2010-06-14 UY UY0001032707A patent/UY32707A/es not_active Application Discontinuation
- 2010-06-14 UA UAA201200408A patent/UA108357C2/ru unknown
- 2010-06-14 PL PL10727154T patent/PL2442870T3/pl unknown
- 2010-06-14 RS RS20140373A patent/RS53414B/en unknown
- 2010-06-14 ES ES10727154.6T patent/ES2480275T3/es active Active
- 2010-06-14 GE GEAP201012529A patent/GEP20146168B/en unknown
- 2010-06-14 WO PCT/JP2010/060408 patent/WO2010147226A1/en active Application Filing
- 2010-06-14 CN CN201080036178.1A patent/CN102458579B/zh not_active Expired - Fee Related
- 2010-06-14 AU AU2010260847A patent/AU2010260847B2/en not_active Ceased
- 2010-06-14 CA CA2765239A patent/CA2765239C/en not_active Expired - Fee Related
- 2010-06-14 MY MYPI2011006107A patent/MY157497A/en unknown
- 2010-06-14 US US12/814,692 patent/US8318722B2/en not_active Expired - Fee Related
- 2010-06-14 KR KR1020127000935A patent/KR101768234B1/ko active IP Right Grant
- 2010-06-14 EP EP10727154.6A patent/EP2442870B1/en active Active
- 2010-06-14 ME MEP-2014-81A patent/ME01835B/me unknown
- 2010-06-14 SI SI201030641T patent/SI2442870T1/sl unknown
- 2010-06-14 PE PE2011002104A patent/PE20121049A1/es active IP Right Grant
- 2010-06-14 DK DK10727154.6T patent/DK2442870T3/da active
- 2010-06-14 AR ARP100102101A patent/AR077094A1/es not_active Application Discontinuation
- 2010-06-14 MX MX2011013081A patent/MX2011013081A/es active IP Right Grant
- 2010-06-14 TW TW104112674A patent/TW201529584A/zh unknown
-
2011
- 2011-07-28 US US13/192,865 patent/US8324201B2/en not_active Expired - Fee Related
- 2011-07-28 US US13/192,845 patent/US8314088B2/en not_active Expired - Fee Related
- 2011-12-04 IL IL216761A patent/IL216761A/en not_active IP Right Cessation
- 2011-12-08 TN TNP2011000630A patent/TN2011000630A1/en unknown
- 2011-12-14 CL CL2011003154A patent/CL2011003154A1/es unknown
- 2011-12-14 DO DO2011000393A patent/DOP2011000393A/es unknown
- 2011-12-20 ZA ZA2011/09370A patent/ZA201109370B/en unknown
-
2012
- 2012-01-13 CO CO12004620A patent/CO6491037A2/es active IP Right Grant
- 2012-01-13 EC ECSP12011603 patent/ECSP12011603A/es unknown
- 2012-01-13 CR CR20120021A patent/CR20120021A/es unknown
- 2012-01-31 JP JP2012019274A patent/JP5579203B2/ja not_active Expired - Fee Related
- 2012-10-19 HK HK12110450.8A patent/HK1169623A1/xx not_active IP Right Cessation
-
2014
- 2014-06-23 HR HRP20140589AT patent/HRP20140589T1/hr unknown
- 2014-06-25 SM SM201400080T patent/SMT201400080B/xx unknown
- 2014-07-11 CY CY20141100527T patent/CY1115483T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140589T1 (hr) | Derivati pirazinooksazepina | |
| GEP201606506B (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| GEP20156348B (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| TNSN08311A1 (en) | Indole sulfonamide modulators of progesterone receptors | |
| PE20160844A1 (es) | Compuestos triciclicos como agentes anticancerigenos | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| PE20070172A1 (es) | DERIVADOS BICICLICOS COMO INHIBIDORES DE p38 | |
| DE602006011609D1 (de) | Organische verbindungen zur behandlung entzündlicher oder allergischer leiden | |
| ME01089B (me) | Derivat benzimidazola i njegova upotreba kao antagonista receptora aii | |
| DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
| NZ602754A (en) | Substituted 1,3-benzothiazepines useful in treating metabolic disorders | |
| NZ596579A (en) | Bace inhibitors | |
| ATE542799T1 (de) | Chinolinonderivate als parp und tank-inhibitoren | |
| PE20121085A1 (es) | Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9 (10)-dien-11-arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades | |
| HRP20140687T1 (hr) | Derivati benzofurana | |
| NO20090979L (no) | (3-amino-1,2,3,4-tetrahydro-9H-karbazol-9-yl)-eddiksyrederivater | |
| ATE484502T1 (de) | Neue verbindungen | |
| PE20091436A1 (es) | Derivados de sulfonamidas sustituidas como moduladores b1r | |
| ATE528306T1 (de) | Benzoxazepin-verbindungen, ihre herstellung und verwendung | |
| EA201100368A1 (ru) | Амидные соединения, полезные в терапии | |
| MX2011011303A (es) | Derivados de isoxazol. | |
| MX2009005507A (es) | Derivados de espiro-piperidina. | |
| TW200833697A (en) | Spiro-piperidine derivatives | |
| DE602007011971D1 (de) | Diaminocyclohexan- und diaminocyclopentanderivate | |
| ATE412636T1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas |